Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial

被引：24

作者：

Cheng, Ying ^{[1
]}

Chen, Jianhua ^{[2
]}

Zhang, Wei ^{[3
]}

Xie, Chao ^{[4
]}

Hu, Qun ^{[5
]}

Zhou, Ningning ^{[6
]}

Huang, Chun ^{[7
]}

Wei, Shihong ^{[8
]}

Sun, Hong ^{[9
]}

Li, Xingya ^{[10
]}

Yu, Yan ^{[11
]}

Lai, Jinhuo ^{[12
]}

Yang, Huaping ^{[13
]}

Fang, Haohui ^{[14
]}

Chen, Hualin ^{[15
]}

Zhang, Peng ^{[16
]}

Gu, Kangsheng ^{[17
]}

Wang, Qiming ^{[18
]}

Shi, Jianhua ^{[19
]}

Yi, Tienan ^{[20
]}

Xu, Xingxiang ^{[21
]}

Ye, Xianwei ^{[22
]}

Wang, Daqing ^{[23
]}

Xie, Conghua ^{[24
]}

Liu, Chunling ^{[25
]}

Zheng, Yulong ^{[26
]}

Lin, Daren ^{[27
]}

Zhuang, Wu ^{[28
]}

Lu, Ping ^{[29
]}

Yu, Guohua ^{[30
]}

Li, Jinzhang ^{[31
]}

Gu, Yuhai ^{[32
]}

Li, Baolan ^{[33
]}

Wu, Rong ^{[34
]}

Jiang, Ou ^{[35
]}

Wang, Zaiyi ^{[36
]}

Wu, Guowu ^{[37
]}

Lin, Haifeng ^{[38
]}

Zhong, Diansheng ^{[39
]}

Xu, Yanhua ^{[40
]}

Shu, Yongqian ^{[41
]}

Wu, Di ^{[42
]}

Chen, Xingwu ^{[43
]}

Wang, Jie ^{[44
]}

Wang, Minghui ^{[45
]}

Yang, Runxiang ^{[46
]}

机构：

[1] Jilin Canc Hosp, Changchun, Peoples R China

[2] Hunan Canc Hosp, Changsha, Peoples R China

[3] Nanchang Univ, Affiliated Hosp 1, Nanchang, Peoples R China

[4] Shandong Univ, Shandong Canc Hosp & Inst, Jinan, Peoples R China

[5] Inner Mongolia Univ, Affiliated Hosp, Hohhot, Peoples R China

[6] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China

[7] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China

[8] Gansu Prov Canc Hosp, Lanzhou, Peoples R China

[9] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China

[10] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[11] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China

[12] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China

[13] Cent South Univ, Xiangya Hosp, Changsha, Peoples R China

[14] Anhui Chest Hosp, Hefei, Peoples R China

[15] Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China

[16] Shanghai Pulm Hosp, Shanghai, Peoples R China

[17] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China

[18] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[19] Linyi Canc Hosp, Linyi, Peoples R China

[20] Xiangyang Cent Hosp, Xiangyang, Peoples R China

[21] Northern Jiangsu Peoples Hosp, Yangzhou, Peoples R China

[22] Guizhou Prov Peoples Hosp, Guiyang, Peoples R China

[23] Hengshui Peoples Hosp, Hengshui, Peoples R China

[24] Wuhan Univ, Zhongnan Hosp, Wuhan, Peoples R China

[25] Xinjiang Med Univ, Canc Hosp, Urumqi, Peoples R China

[26] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China

[27] Jiangmen Cent Hosp, Jiangmen, Peoples R China

[28] Fujian Canc Hosp, Fuzhou, Peoples R China

[29] Xinxiang Med Coll, Affiliated Hosp 1, Xinxiang, Peoples R China

[30] Weifang Peoples Hosp, Weifang, Peoples R China

[31] Qinghai Univ, Affiliated Hosp, Xining, Peoples R China

[32] Qinghai Prov Peoples Hosp, Xining, Peoples R China

[33] Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China

[34] China Med Univ, Shengjing Hosp, Shenyang, Peoples R China

[35] Second Peoples Hosp Neijiang, Neijiang, Peoples R China

[36] Xinjiang Med Univ, Affiliated Hosp 1, Urumqi, Peoples R China

[37] Meizhou Peoples Hosp, Meizhou, Peoples R China

[38] Hainan Med Univ, Affiliated Hosp 2, Haikou, Peoples R China

[39] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China

[40] Jingzhou Cent Hosp, Jingzhou, Peoples R China

[41] Jiangsu Prov Hosp, Nanjing, Peoples R China

[42] Shenzhen Peoples Hosp, Shenzhen, Peoples R China

[43] Wannan Med Coll, Affiliated Hosp 1, Wuhu, Peoples R China

[44] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China

[45] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China

[46] Yunnan Canc Hosp, Kunming, Peoples R China

来源：

NATURE MEDICINE | 2024年 / 30卷 / 10期

关键词：

COMBINATION; SURVIVAL; EFFICACY; CRITERIA; TQB2450; IB;

D O I：

10.1038/s41591-024-03132-1

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Immunochemotherapy is the first-line standard for extensive-stage small-cell lung cancer (ES-SCLC). Combining the regimen with anti-angiogenesis may improve efficacy. ETER701 was a multicenter, double-blind, randomized, placebo-controlled phase 3 trial that investigated the efficacy and safety of benmelstobart (a novel programmed death-ligand 1 (PD-L1) inhibitor) with anlotinib (a multi-target anti-angiogenic small molecule) and standard chemotherapy in treatment-naive ES-SCLC. The ETER701 trial assessed two primary endpoints: Independent Review Committee-assessed progression-free survival per RECIST 1.1 and overall survival (OS). Here the prespecified final progression-free survival and interim OS analysis is reported. Patients randomly received benmelstobart and anlotinib plus etoposide/carboplatin (EC; n = 246), placebo and anlotinib plus EC (n = 245) or double placebo plus EC ('EC alone'; n = 247), followed by matching maintenance therapy. Compared with EC alone, median OS was prolonged with benmelstobart and anlotinib plus EC (19.3 versus 11.9 months; hazard ratio 0.61; P = 0.0002), while improvement of OS was not statistically significant with anlotinib plus EC (13.3 versus 11.9 months; hazard ratio 0.86; P = 0.1723). The incidence of grade 3 or higher treatment-related adverse events was 93.1%, 94.3% and 87.0% in the benmelstobart and anlotinib plus EC, anlotinib plus EC, and EC alone groups, respectively. This study of immunochemotherapy plus multi-target anti-angiogenesis as first-line treatment achieved a median OS greater than recorded in prior randomized studies in patients with ES-SCLC. The safety profile was assessed as tolerable and manageable. Our findings suggest that the addition of anti-angiogenesis therapy to immunochemotherapy may represent an efficacious and safe approach to the management of ES-SCLC. ClinicalTrials.gov identifier: NCT04234607. In this triple-arm, placebo-controlled phase 3 trial, first-line treatment of patients with extensive-stage small-cell lung cancer with the anti-PD-L1 benmelstobart, tyrosine kinase inhibitor anlotinib and chemotherapy (CT) showed improved survival outcomes compared with anlotinib and CT or CT alone.

引用

页码：1819 / 1822

页数：19

共 50 条

[21] Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
Spigel, David R.
Townley, Peter M.
Waterhouse, David M.
Fang, Liang
Adiguzel, Ibrahim
Huang, Jane E.
Karlin, David A.
Faoro, Leonardo
Scappaticci, Frank A.
Socinski, Mark A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2215 - 2222
[22] Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer
Socinski, Mark A.
Weissman, Charles
Hart, Lowell L.
Beck, J. Thaddeus
Choksi, Janak K.
Hanson, John P.
Prager, Diane
Monberg, Matthew J.
Ye, Zhishen
Obasaju, Coleman K.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4840 - 4847
[23] Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer
Lara, Primo N., Jr.
Gandara, David R.
Natale, Ronald B.
CLINICAL LUNG CANCER, 2006, 7 (05) : 353 - 356
[24] Anlotinib as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer: A Single-arm, Prospective, Phase II Study
Kong, F.
Wang, Z.
Wang, N.
Zhang, D.
Liao, D.
Zhang, J.
Su, C.
Jia, Y.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S691 - S692
[25] Re: A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer
Buyse, M
Thirion, P
Carlson, RW
Burzykowski, T
Molenberghs, G
Piedbois, P
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (05) : 399 - 400
[26] Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
Nogami, Naoyuki
Tokito, Takaaki
Zenke, Yoshitaka
Satouchi, Miyako
Seto, Takashi
Saka, Hideo
Ohtani, Junko
Han, Shirong
Noguchi, Kazuo
Nishio, Makoto
INVESTIGATIONAL NEW DRUGS, 2024, 42 (01) : 136 - 144
[27] Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
Naoyuki Nogami
Takaaki Tokito
Yoshitaka Zenke
Miyako Satouchi
Takashi Seto
Hideo Saka
Junko Ohtani
Shirong Han
Kazuo Noguchi
Makoto Nishio
Investigational New Drugs, 2024, 42 : 136 - 144
[28] The Efficacy and Toxicity of Lobaplatin-contained Chemotherapy in Extensive-stage Small-cell Lung Cancer
Zhou, Ning-ning
Zhou, Yuan-yuan
Zhai, Lin-zhu
Ruan, Chao-mei
Yang, Yun-peng
Huang, Yan
Hou, Xue
Chen, Li-kun
Zhou, Ting
Zhang, Li
JOURNAL OF CANCER, 2018, 9 (13): : 2232 - 2236
[29] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Horn, L.
Mansfield, A. S.
Szczesna, A.
Havel, L.
Krzakowski, M.
Hochmair, M. J.
Huemer, F.
Losonczy, G.
Johnson, M. L.
Nishio, M.
Reck, M.
Mok, T.
Lam, S.
Shames, D. S.
Liu, J.
Ding, B.
Lopez-Chavez, A.
Kabbinavar, F.
Lin, W.
Sandler, A.
Liu, S. V.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23): : 2220 - 2229
[30] Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer
Spigel, David R.
Greco, F. Anthony
Zubkus, John D.
Murphy, Patrick B.
Saez, Ruben A.
Farley, Cindy
Yardley, Denise A.
Burris, Howard A., III
Hainsworth, John D.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (12) : 1555 - 1560

← 1 2 3 4 5 →